"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...
BERLIN — A novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist combined into a single drug (LY3298176, Lilly), dubbed a "twincretin," ...
LOS ANGELES, CA / ACCESS Newswire / August 26, 2025 / LifeRx.md today announced a definitive expansion of its clinical services. After establishing a permanent leadership position in GLP and GIP ...
Eli Lilly and Company announced detailed results from SURPASS-PEDS, the first phase 3 trial to evaluate the safety and efficacy of Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, in ...
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week ...
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated ...
Hosted on MSN
The Next Ozempic? New 4-in-1 Weight Loss Drug Could Treat Obesity, Diabetes, Cancer And Heart Diseases
What if a single shot could help you lose weight, lower your risk of diabetes, protect your heart, and even cut your chances of developing certain cancers? That’s the promise scientists at Tufts ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback